Lannett Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA, Inc, has launched the generic equivalent of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in the US market in 100/50 mcg and 250/50 mcg strengths. The launch marks the first commercialized product from Aurobindo Pharma’s inhalation pipeline in the US and strengthens the company’s focus on developing and supplying complex and differentiated inhalation products.
Advair Diskus is a combination therapy indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The launch expands Aurobindo Pharma’s US portfolio and adds an inhalation product to its growing range of generic medicines. Aurobindo Pharma said the introduction of the product reflects its continued investment in product development and its ability to bring complex pharmaceutical products to regulated markets.
The company has been expanding its presence across major therapeutic segments through investments in research and development, manufacturing and regulatory capabilities. Its portfolio covers areas including central nervous system therapies, anti-retroviral medicines, cardiovascular products, antibiotics, gastroenterology, anti-diabetic medicines and anti-allergic treatments.
Aurobindo Pharma Limited is an integrated pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures and markets generic pharmaceuticals, branded specialty products and active pharmaceutical ingredients in more than 150 countries.
The company operates more than 30 manufacturing and packaging facilities. These facilities are approved by regulatory agencies in major markets, including the US Food and Drug Administration, UK Medicines and Healthcare products Regulatory Agency, European Directorate for the Quality of Medicines, Japan’s Pharmaceuticals and Medical Devices Agency, World Health Organization, Health Canada, South Africa’s Medicines Control Council and Brazil’s health regulator ANVISA.
The launch of the generic inhalation product also supports Aurobindo Pharma’s strategy of expanding beyond conventional oral solid dosage products into more complex formulations and delivery systems. The company’s strong research and development infrastructure supports the development of new products across multiple therapeutic areas. The US launch of the generic Advair Diskus equivalent represents an important step in commercializing its inhalation pipeline and strengthening its position in the US generic pharmaceutical market.
Aurobindo Pharma continues to focus on developing affordable medicines and expanding access to pharmaceutical products across global markets. With its manufacturing network, regulatory experience and growing product pipeline, the company aims to further strengthen its presence in complex and specialized pharmaceutical segments.
